Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required. Methods: We evaluated anti-cancer activity of a potent proteasome inhibitor, marizomib, in vitro using breast cancer lines and in vivo using 4T1.2 murine syngeneic model, MDA-MB-231 xenografts, and patient-derived tumor xenografts. Global proteome profiling, western blots, and RT-qPCR were used to investigate the mechanism of action for marizomib. Effect of marizomib on lung and brain metastasis was evaluated using syngeneic 4T1BR4 murine TNBC model in vivo. Results: We show that marizomib inhibits multiple proteasome catalytic activities and induces a better anti-tumor response in TNBC cell lines and patient-derived xenografts alone and in combination with the standard-of-care chemotherapy. Mechanistically, we show that marizomib is a dual inhibitor of proteasome and oxidative phosphorylation (OXPHOS) in TNBCs. Marizomib reduces lung and brain metastases by reducing the number of circulating tumor cells and the expression of genes involved in the epithelial-to-mesenchymal transition. We demonstrate that marizomib-induced OXPHOS inhibition upregulates glycolysis to meet the energetic demands of TNBC cells and combined inhibition of glycolysis with marizomib leads to a synergistic anti-cancer activity. Conclusions: Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.

Institute of Biotechnology Czech Academy of Sciences Prague West 252 50 Czech Republic

Olivia Newton John Cancer Research Institute 145 Studley Road Heidelberg Vic 3084 Australia

QIMR Berghofer Medical Research Institute 300 Herston Road Herston Brisbane QLD 4006 Australia

Radiation Biology Research Center Institute for Radiological Research Chang Gung Memorial Hospital Chang Gung University Taoyuan 333 Taiwan

School of Medical Science Griffith University Southport QLD 4222 Australia

UQ Centre for Clinical Research Faculty of Medicine The University of Queensland Herston QLD 4029 Australia

Zobrazit více v PubMed

Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends Pharmacol Sci. 2015;36:822–46. PubMed

Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ. et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013;24:182–96. PubMed PMC

Stingele S, Stoehr G, Peplowska K, Cox J, Mann M, Storchova Z. Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cells. Mol syst biol. 2012;8:608. PubMed PMC

Dou QP, Zonder JA. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 2014;14:517–36. PubMed PMC

Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E. et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18:897–909. PubMed

Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739–58. PubMed

Groll M, Heinemeyer W, Jager S, Ullrich T, Bochtler M, Wolf DH. et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci U S A. 1999;96:10976–83. PubMed PMC

Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M. et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8:407–19. PubMed

Arendt CS, Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci U S A. 1997;94:7156–61. PubMed PMC

Weyburne ES, Wilkins OM, Sha Z, Williams DA, Pletnev AA, de Bruin G. et al. Inhibition of the Proteasome beta2 Site Sensitizes Triple-Negative Breast Cancer Cells to beta5 Inhibitors and Suppresses Nrf1 Activation. Cell Chem Biol. 2017;24:218–30. PubMed PMC

Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B. et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem. 2005;48:3684–7. PubMed

Levin N, Spencer A, Harrison SJ, Chauhan D, Burrows FJ, Anderson KC. et al. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016;174:711–20. PubMed PMC

Manton CA, Johnson B, Singh M, Bailey CP, Bouchier-Hayes L, Chandra J. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. Sci Rep. 2016;6:18953. PubMed PMC

Spencer A, Harrison S, Zonder J, Badros A, Laubach J, Bergin K. et al. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. Br J Haematol. 2018;180:41–51. PubMed PMC

Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev. 2002;16:693–706. PubMed PMC

Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Mol Med. 2018. 10. PubMed PMC

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B. et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011;11:254–84. PubMed PMC

Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M. et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007;110:267–77. PubMed PMC

Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D. et al. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011;71:5164–74. PubMed PMC

Shen L, O'Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL. et al. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci U S A. 2015;112:5425–30. PubMed PMC

Meric-Bernstam KE, Zheng X, Su X, Yuca E, Scott S, Akcakanat A, Oxidative phosphorylation as a target in triple negative breast cancer therapy [abstract] Proc Annu Meet Am Assoc Cancer Res. 2017. 77.

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G. et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615–21. PubMed

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106:13820–5. PubMed PMC

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84. PubMed

Qi XS, Pajonk F, McCloskey S, Low DA, Kupelian P, Steinberg M. et al. Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation. Radiother Oncol. 2017;124:455–61. PubMed PMC

Kim SH, Redvers RP, Chi LH, Ling X, Lucke AJ, Reid RC, Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis. Dis Model Mech. 2018. 11. PubMed PMC

Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene. 2009;28:3573–85. PubMed

Andrzejewski S, Klimcakova E, Johnson RM, Tabaries S, Annis MG, McGuirk S. et al. PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell metab. 2017;26:778–87. PubMed

LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC. et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16:992–1003. 1-15. PubMed PMC

Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL. et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest. 2018;128:1371–83. PubMed PMC

Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella JF, Corneau S. et al. Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. Cancer Cell. 2019;36:84–99. e8. PubMed

Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S. et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer invest. 2007;25:733–7. PubMed

Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S. et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006;17:813–7. PubMed

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X. et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108–21. PubMed

Trinh XB, Sas L, Van Laere SJ, Prove A, Deleu I, Rasschaert M. et al. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncol rep. 2012;27:657–63. PubMed

Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S. et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;10:3371–6. PubMed

O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF. et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15:7085–91. PubMed PMC

Cusack JC Jr, Liu R, Xia L, Chao TH, Pien C, Niu W. et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res. 2006;12:6758–64. PubMed

Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D. et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res. 2008;14:5116–23. PubMed PMC

Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P. et al. Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. Transl oncol. 2010;3:50–5. PubMed PMC

Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S. et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol cell. 2012;47:570–84. PubMed PMC

Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW. et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer. 2011;129:820–31. PubMed

Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V. et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26:1926–44. PubMed PMC

Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M. et al. MYC/PGC-1alpha Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell metab. 2015;22:590–605. PubMed

Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329–41. PubMed PMC

Luo M, Shang L, Brooks MD, Jiagge E, Zhu Y, Buschhaus JM. et al. Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling. Cell metab. 2018;28:69–86. e6. PubMed PMC

Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638–45. PubMed PMC

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34. PubMed

Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A. et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro-oncol. 2016;18:840–8. PubMed PMC

Structural Insights into Salinosporamide a Mediated Inhibition of the Human 20S Proteasome

Structural insights into Salinosporamide A mediated inhibition of the human 20S proteasome